Baxalta Gmbh

Baxter International Inc.

Baxter Healthcare Sa

Immuno Aktiengesellschaft

Baxter Aktiengesellschaft

Takeda Pharmaceutical Company Limited

Nektar Therapeutics

Baxter Innovations Gmbh

Stichting Sanquin Bloedvoorziening

Lipoxen Technologies Incorporated

Baxter Healthcare Inc.

Baxler Innovations Gmbh

Immuno Aktiengesllschaft

Peter Turecek

Hans-Peter Schwarz

Juergen Siekmann

Friedrich Scheiflinger

Hanspeter Rottensteiner

Johann J Eibl

Katalin Varadi

Peter Matthiessen

Stefan Haider

Herbert Gritsch

Alfred Weber

Miha Furlan

Klaus Zimmermann

Bernhard Laemmle

Hans Peter Schwarz

Randolf Kerschbaumer

Gerhard Antoine

Luigina Tagliavacca

Jutta Schreiner

Friedrich Dorner

Bernhard Fischer

Artur Mitterer

Helena Elisabeth Schaller-Gerritsen

Manfred Reiter

Wolfgang Mundt

Zhihao Fang

Mary J Bossard

Ping Zhang

Falko-Guenter Falkner

Uwe Schlokat

Kurt Schnecker

Harold Zappe

Heinz Anderle

Renate Den-Bouwmeester

Gerda Redl

Susanne Vejda

Daniel R Boggs

Thomas Seelich

Koenraad Mertens

Gayle Stephenson

Thomas R Kreil

Stacy Mitchell

Hans Pannekoek

Jan Aart Van Mourik

Petrus Johannes Lenting

Eva Haidweger

Andreas Ivens

Sanjay Jain

Gregory Gregoriadis

Michael Dockal

Hendrik Coenraad Hemker

Christian R Noe

Gunter Wober

Suzette Lucette Beguin

Oliver Zoechling

Archana Dwivedi

Srijit Nath

Michel Canavaggio

Gerhard Stoiber

Gabriela Hummel

Yendra Linnau

Sean M Culbertson

Ludwig Pichler

Otto Schwarz

Joris Hoefinghoff

Bruce Ewenstein

Eva-Maria Muchitsch

Friedrich Elsinger

Gunther Wober

Susanne Till

Erwin Mattes

Sabine Knappe

Gerald Schrenk

Jurgen Siekmann

Eibl Johann

Manfred Rieger

Dirk V&ouml;lkel

Tobias M Suiter

Wing Yen Wong

Richard Sheinecker

Jueren Siekmann

Brigitte Keil

Sylvia Peyrer-Heimstaett

Stefan Romeder-Finger

Gerald Brachtl

Helena Elisabeth Gerritsen

Richard Scheinecker

Christian Noe

The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.

Stabilized liquid and lyophilized ADAMTS13 formulations

The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst.

Nucleophilic catalysts for oxime linkage

Long-term stable pharmaceutical formulations of lyophilized recombinant von-Willebrand Factor (rVWF) and methods for making and administering said formulations are described.

Lyophilized recombinant VWF formulations

The present invention provides long-term stable pharmaceutical formulations of recombinant von-Willebrand Factor (rVWF) and methods for making and administering said formulations.

Recombinant VWF formulations

Disclosed herein are compositions and methods for improving hemostasis in the treatment of bleeding disorders and reversal of anticoagulant activity. Effective ratios of prothrombin (FII) and activated factor X (FXa) for the treatment of bleeding disorders that are as efficacious as FEIBA&#xae;, but require a lower concentration of FII are described herein.

Compositions of human prothrombin and activated factor X for improving hemostasis in the treatment of bleeding disorders

The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a blood coagulation protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer. In one embodiment of the invention the conjugation is carried out in the presence of the nucleophilic catalyst aniline. In addition the generated oxime linkage can be stabilized by reduction with NaCNBHto form an alkoxyamine linkage.

Blood coagulation protein conjugates

The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.

Factor VIII polymer conjugates

The invention generally relates to methods of testing the effectiveness of a von Willebrand factor (VWF) in treating von Willebrand disease (VWD) in a subject comprising measuring VWF cleavage fragments in a blood sample from the subject before and after treatment. In particular, the invention relates to methods of measuring VWF cleavage fragments, wherein an increase in VWF cleavage fragments after the treatment indicates that endogenous a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) in the subject is cleaving the VWF and wherein a decrease or absence of VWF cleavage fragments after the treatment indicates that endogenous ADAMTS13 in the subject is not cleaving the VWF.

Methods for testing effectiveness of a von Willebrand factor used in treating von Willebrand disease (VWD)

A water soluble polymer, in particular polysialic acid (PSA) or a modified PSA (mPSA), is conjugated to an oxidized carbohydrate moiety of a glycoprotein other than a blood coagulation protein or to a ganglioside or drug delivery system by contacting the oxidized carbohydrate moiety with the water soluble polymer, wherein said water soluble polymer contains an aminooxy group and an oxime linkage is formed between the oxidized carbohydrate moiety and the aminooxy group on the water soluble polymer or wherein said water soluble polymer contains a hydrazide group and a hydrazone linkage is formed between the oxidized carbohydrate moiety and the hydrazide group on the water soluble polymer. Conjugates of aminooxy- or hydrazide-water soluble polymer, such as PSA and mPSA, are thus obtained in which the PSA or mPSA is attached via a carbohydrate moiety.

Glycopolysialylation of non-blood coagulation proteins

Growing community of inventors

Klosterneuburg, Austria

Peter Turecek